CRISPR/CAS9 KNOCKOUT OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS

被引：0

作者：

Albinger, Nawid ^{[1
,2
]}

Bexte, Tobias ^{[1
,2
,3
]}

Al-Ajami, Ahmad ^{[2
,3
,4
]}

Wendel, Philipp ^{[1
,2
]}

Buchinger, Leon ^{[1
,2
]}

Gessner, Alec ^{[2
,3
,5
]}

Sarchen, Vinzenz ^{[6
]}

Alzubi, Jamal ^{[7
]}

Mertlitz, Sarah ^{[8
]}

Penack, Olaf ^{[8
]}

Bhayadia, Raj ^{[1
,2
,3
]}

Heckl, Dirk ^{[9
]}

Klusmann, Jan-Henning ^{[1
,2
,3
]}

Vogler, Meike ^{[6
]}

Moeker, Nina ^{[10
]}

Cathomen, Toni ^{[7
]}

Rieger, Michael A. ^{[2
,3
,11
]}

Imkeller, Katharina ^{[2
,3
,4
]}

Ullrich, Evelyn ^{[1
,2
,3
,11
]}

机构：

[1] Goethe Univ Frankfurt, Frankfurt, Germany

[2] Frankfurt Canc Inst, Frankfurt, Germany

[3] Univ Canc Ctr UCT, Frankfurt, Germany

[4] Univ Hosp Frankfurt, Neurol Inst Edinger Inst, Frankfurt, Germany

[5] Univ Hosp Frankfurt, Frankfurt, Germany

[6] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Frankfurt, Germany

[7] Med Ctr Univ Freiburg, Inst Transfus Med & Gene Therapy, Freiburg, Germany

[8] Charite Med Berlin, Berlin, Germany

[9] Martin Luther Univ Halle Wittenberg, Pediat Hematol & Oncol, Halle, Germany

[10] Miltenyi Biotec BV Co KG, Bergisch Gladbach, Germany

[11] German Canc Consortium DKTK Partner Site Frankf, Frankfurt, Germany

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O042

引用

页码：46 / 47

页数：2

共 7 条

[1] CRISPR/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML
Ullrich, E.
Albinger, N.
Bexte, T.
Al-Ajami, A.
Gessner, A.
Alzubi, J.
Wolf, S.
Oellerich, T.
Bhayadia, R.
Klusmann, J. -H.
Moeker, N.
Cathomen, T.
Rieger, M. A.
Imkeller, K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 123 - 123
[2] CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML
Albinger, Nawid
Bexte, Tobias
Buchinger, Leon
Wendel, Philipp
Al-Ajami, Ahmad
Gessner, Alec
Saerchen, Vinzenz
Alzubi, Jamal
Mertlitz, Sarah
Penack, Olaf
Bhayadia, Raj
Klusmann, Jan-Henning
Vogler, Meike
Moeker, Nina
Cathomen, Toni
Rieger, Michael A.
Imkeller, Katharina
Ullrich, Evelyn
BLOOD, 2022, 140 : 4558 - 4559
[3] Knock-out of inhibitory receptor NKG2A improves efficacy of CD33-targeting CAR-NK cells against AML
Albinger, N.
Bexte, T.
Buchinger, L.
Wendel, P.
Al-Ajami, A.
Gessner, A.
Saehen, V.
Alzubi, J.
Mertlitz, S.
Penack, O.
Bhayadia, R.
Vogler, M.
Heckl, D.
Klusmann, J. -H.
Moeker, N.
Cathomen, T.
Rieger, M. A.
Imkeller, K.
Ullrich, E.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 138 - 139
[4] CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
Bexte, Tobias
Albinger, Nawid
Al Ajami, Ahmad
Wendel, Philipp
Buchinger, Leon
Gessner, Alec
Alzubi, Jamal
Saerchen, Vinzenz
Vogler, Meike
Rasheed, Hadeer Mohamed
Jung, Beate Anahita
Wolf, Sebastian
Bhayadia, Raj
Oellerich, Thomas
Klusmann, Jan-Henning
Penack, Olaf
Moeker, Nina
Cathomen, Toni
Rieger, Michael A.
Imkeller, Katharina
Ullrich, Evelyn
NATURE COMMUNICATIONS, 2024, 15 (01)
[5] CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity
Kararoudi, Meisam Naeimi
Likhite, Shibi
Elmas, Ezgi
Schwartz, Maura
Sorathia, Kinnari
Yamamoto, Kenta
Chakravarti, Nitin
Moriarity, Branden S.
Meyer, Kathrin
Lee, Dean Anthony
BLOOD, 2020, 136
[6] Primary NK cells modified by CD33-CAR insertion and CRISPR/Cas9-based disruption of the KLRC1 gene mediate high efficacy against acute myeloid leukemia
Bexte, Tobias
Albinger, Nawid
Al-Ajami, Ahmad
Wendel, Philipp
Alzubi, Jamal
Gessner, Alec
Wolf, Sebastian
Rasheed, Hadeer Mohamed
Jung, Beate Anahita
Penack, Olaf
Oellerich, Thomas
Klusmann, Jan Henning
Cathomen, Toni
Rieger, Michael
Imkeller, Katharina
Ulinch, Evelyn
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 307 - 307
[7] CRISPR/CAS9 GENE-EDITED ALLOGENEIC CAR-T CELLS TARGETING CD33 SHOW HIGH PRECLINICAL EFFICACY AGAINST AML WITHOUT LONG-TERM HEMATOPOIETIC TOXICITY
Terrett, Jonathan
Mcewan, Brigid
Hostetter, Daniel
Gamboa, Luis
Kuppuraju, Meghna
Ghonime, Mohammed
Chain, Robert
Padalia, Zinkal
Kalaitzidis, Demetrios
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A143 - A143

← 1 →